—
00:00
Growing Money
Growing Money
USD/RUB—
EUR/RUB—
Releases

Investors Urged to Join Securities Fraud Class Action Against Anavex

Investors who purchased Anavex Life Sciences Corp. stock between November 26, 2025, and August 28, 2026, face a November 30, 2026, deadline to seek lead plaintiff status in a pending securities fraud lawsuit. The litigation targets alleged misrepresentations regarding internal controls and regulatory risks tied to former CEO Christopher Missling.

Investors Urged to Join Securities Fraud Class Action Against Anavex

The class action, filed by Schall, Brown & Schwartz LLP, claims that Anavex violated the Securities Exchange Act by issuing false and misleading statements to the market. According to the complaint, the company failed to maintain adequate internal controls and obscured significant regulatory headwinds stemming from the conduct of its former executive. These omissions allegedly masked the true financial risk to shareholders, resulting in losses when the market eventually recalibrated based on the disclosed information.

While the class has not yet been certified, shareholders who suffered financial losses during the specified period may contact attorneys Brian Schall or David Schwartz to discuss potential participation. Engaging in the process does not require serving as a lead plaintiff, though those who choose to take no action will remain absent class members without legal representation in the current proceedings.

Share

Comments (0)

Leave a comment

No comments yet. Be the first!